Variable | Undetectable viral load, NÂ =Â 367 | P value | |
---|---|---|---|
Yes, n (%) | No, n (%) | ||
Sex | Â | Â | 0.908 |
 Male | 91 (47.4) | 84 (48.0) |  |
 Female | 101 (52.6) | 91 (52.0) |  |
Age group | Â | Â | 0.163 |
 0–5 | 133 (69.3) | 136 (77.7) |  |
 6–15 | 49 (25.5) | 34 (19.4) |  |
 15–18 | 10 (5.2) | 5 (2.9) |  |
Timing of ART initiation | Â | Â | 0.065 |
 Within 7 days | 103 (53.7) | 77 (44.0) |  |
 Beyond 7 days | 89 (46.3) | 98 (56.0) |  |
Mean baseline weight (SD) | 14.4 (14.0) | 11.1 (9.4) | 0.007* |
Baseline creatinine level | 28.6 (11.2) | 27.6 (12.0) | 0.705 |
Baseline haemoglobin level | 10.02 (1.9) | 9.57 (1.64) | 0.020* |
Adherence on ART | Â | Â | 0.001* |
 Good adherence (Pill count based) (≥3 consecutive visits) | 38 (19.8) | 72 (41.1) |  |
 Inconsistent adherence | 154 (80.2) | 103 (58.9) |  |
Baseline Nutrition status | Â | Â | 0.745 |
 Normal limits & mild malnutrition | 102 (53.1) | 90 (51.4) |  |
 Moderate & severe malnutrition | 90 (46.9) | 85 (48.6) |  |
TB status | Â | Â | 0.067 |
 Positive | 15 (7.8) | 24 (13.7) |  |
 Negative | 177 (92.2) | 151 (86.3) |  |
Baseline ART regimen | Â | Â | 0.121 |
 Nevirapine based | 66 (34.4) | 77 (44.0) |  |
 Efavirenz based | 44 (22.9) | 28 (16.0) |  |
 Protease Inhibitor based | 75 (39.1) | 60 (34.3) |  |
 Triple RTI | 7 (3.7) | 10 (5.7) |  |
WHO clinical stage | Â | Â | 0.089 |
 I & II | 79 (41.2) | 57 (32.6) |  |
 III & IV | 113 (58.8) | 118 (67.4) |  |